BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Oakes RS, Kirkham JK, Nelson RD, Siegler RL. Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 2008;23:1303-8. [PMID: 18465151 DOI: 10.1007/s00467-008-0799-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 McKee RS, Schnadower D, Tarr PI, Xie J, Finkelstein Y, Desai N, Lane RD, Bergmann KR, Kaplan RL, Hariharan S, Cruz AT, Cohen DM, Dixon A, Ramgopal S, Rominger A, Powell EC, Kilgar J, Michelson KA, Beer D, Bitzan M, Pruitt CM, Yen K, Meckler GD, Plint AC, Bradin S, Abramo TJ, Gouin S, Kam AJ, Schuh A, Balamuth F, Hunley TE, Kanegaye JT, Jones NE, Avva U, Porter R, Fein DM, Louie JP, Freedman SB; Pediatric Emergency Medicine Collaborative Research Committee and Pediatric Emergency Research Canada. Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin-producing Escherichia coli-infected Children. Clin Infect Dis 2020;70:1643-51. [PMID: 31125419 DOI: 10.1093/cid/ciz432] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
2 Cheung V, Trachtman H. Hemolytic uremic syndrome: toxins, vessels, and inflammation. Front Med (Lausanne) 2014;1:42. [PMID: 25593915 DOI: 10.3389/fmed.2014.00042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
3 Bertholet-thomas A, Ranchin B, King L, Bacchetta J, Belot A, Gillet Y, Collardeau-frachon S, Cochat P. Syndrome hémolytique et urémique post-diarrhéique : Quand y penser ? Quel suivi ? Archives de Pédiatrie 2011;18:823-30. [DOI: 10.1016/j.arcped.2011.04.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
4 Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS. Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 2013;28:2097-105. [DOI: 10.1007/s00467-012-2383-6] [Cited by in Crossref: 110] [Cited by in F6Publishing: 81] [Article Influence: 12.2] [Reference Citation Analysis]
5 Boyer O, Niaudet P. Hemolytic uremic syndrome: new developments in pathogenesis and treatment. Int J Nephrol 2011;2011:908407. [PMID: 21876803 DOI: 10.4061/2011/908407] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
6 Andreoli SP. Clinical Evaluation of Acute Kidney Injury in Children. In: Avner E, Harmon W, Niaudet P, Yoshikawa N, editors. Pediatric Nephrology. Berlin: Springer Berlin Heidelberg; 2009. pp. 1603-18. [DOI: 10.1007/978-3-540-76341-3_65] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
7 Trachtman H. HUS and TTP in Children. Pediatr Clin North Am 2013;60:1513-26. [PMID: 24237985 DOI: 10.1016/j.pcl.2013.08.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
8 Caletti MG, Balestracci A, Roy AH. Levels of urinary transforming growth factor β-1 in children with D+ hemolytic uremic syndrome. Pediatr Nephrol 2010;25:1177-80. [DOI: 10.1007/s00467-009-1434-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
9 Mayer CL, Leibowitz CS, Kurosawa S, Stearns-Kurosawa DJ. Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins (Basel) 2012;4:1261-87. [PMID: 23202315 DOI: 10.3390/toxins4111261] [Cited by in Crossref: 86] [Cited by in F6Publishing: 68] [Article Influence: 8.6] [Reference Citation Analysis]
10 Bruyand M, Mariani-Kurkdjian P, Gouali M, de Valk H, King LA, Le Hello S, Bonacorsi S, Loirat C. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Med Mal Infect 2018;48:167-74. [PMID: 29054297 DOI: 10.1016/j.medmal.2017.09.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
11 Loos S, Aulbert W, Hoppe B, Ahlenstiel-Grunow T, Kranz B, Wahl C, Staude H, Humberg A, Benz K, Krause M, Pohl M, Liebau MC, Schild R, Lemke J, Beringer O, Müller D, Härtel C, Wigger M, Vester U, Konrad M, Haffner D, Pape L, Oh J, Kemper MJ. Intermediate Follow-up of Pediatric Patients With Hemolytic Uremic Syndrome During the 2011 Outbreak Caused by E. coli O104:H4. Clin Infect Dis 2017;64:1637-43. [PMID: 28329394 DOI: 10.1093/cid/cix218] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
12 Robitaille P, Clermont MJ, Mérouani A, Phan V, Lapeyraque AL. Hemolytic uremic syndrome: late renal injury and changing incidence-a single centre experience in Canada. Scientifica (Cairo) 2012;2012:341860. [PMID: 24278685 DOI: 10.6064/2012/341860] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Pundzienė B, Dobilienė D, Čerkauskienė R, Mitkienė R, Medzevičienė A, Darškuvienė E, Jankauskienė A. Long-term follow-up of children with typical hemolytic uremic syndrome. Medicina (Kaunas) 2015;51:146-51. [PMID: 28705476 DOI: 10.1016/j.medici.2015.06.004] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Keenswijk W, Vanmassenhove J, Raes A, Dhont E, Vande Walle J. Blood urea nitrogen to serum creatinine ratio is an accurate predictor of outcome in diarrhea-associated hemolytic uremic syndrome, a preliminary study. Eur J Pediatr 2017;176:355-60. [DOI: 10.1007/s00431-016-2846-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
15 Hickey CA, Beattie TJ, Cowieson J, Miyashita Y, Strife CF, Frem JC, Peterson JM, Butani L, Jones DP, Havens PL, Patel HP, Wong CS, Andreoli SP, Rothbaum RJ, Beck AM, Tarr PI. Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 2011;165:884-9. [PMID: 21784993 DOI: 10.1001/archpediatrics.2011.152] [Cited by in Crossref: 83] [Cited by in F6Publishing: 64] [Article Influence: 7.5] [Reference Citation Analysis]
16 Bitzan M, Lapeyraque A. Postinfectious Hemolytic Uremic Syndrome. In: Geary DF, Schaefer F, editors. Pediatric Kidney Disease. Berlin: Springer Berlin Heidelberg; 2016. pp. 653-731. [DOI: 10.1007/978-3-662-52972-0_26] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
17 Davis TK, Van De Kar NCAJ, Tarr PI, Sperandio V, Hovde CJ. Shiga Toxin/Verocytotoxin-Producing Escherichia coli Infections: Practical Clinical Perspectives. Microbiol Spectr 2014;2. [DOI: 10.1128/microbiolspec.ehec-0025-2014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
18 McKee RS, Tarr PI, Dietzen DJ, Chawla R, Schnadower D. Clinical and Laboratory Predictors of Shiga Toxin-Producing Escherichia coli Infection in Children With Bloody Diarrhea. J Pediatric Infect Dis Soc 2018;7:e116-22. [PMID: 29617871 DOI: 10.1093/jpids/piy025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
19 Rosales A, Hofer J, Zimmerhackl L, Jungraithmayr TC, Riedl M, Giner T, Strasak A, Orth-höller D, Würzner R, Karch H; for the German-Austrian HUS Study Group. Need for Long-term Follow-up in Enterohemorrhagic Escherichia coli–Associated Hemolytic Uremic Syndrome Due to Late-Emerging Sequelae. Clinical Infectious Diseases 2012;54:1413-21. [DOI: 10.1093/cid/cis196] [Cited by in Crossref: 102] [Cited by in F6Publishing: 80] [Article Influence: 10.2] [Reference Citation Analysis]
20 Haddad G, Zhu LF, Rayner DC, Murray AG. Experimental glomerular endothelial injury in vivo. PLoS One 2013;8:e78244. [PMID: 24143262 DOI: 10.1371/journal.pone.0078244] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
21 Percheron L, Gramada R, Tellier S, Salomon R, Harambat J, Llanas B, Fila M, Allain-launay E, Lapeyraque A, Leroy V, Adra A, Bérard E, Bourdat-michel G, Chehade H, Eckart P, Merieau E, Piètrement C, Sellier-leclerc A, Frémeaux-bacchi V, Dimeglio C, Garnier A. Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study. Pediatr Nephrol 2018;33:1385-94. [DOI: 10.1007/s00467-018-3903-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
22 Vaterodt L, Holle J, Hüseman D, Müller D, Thumfart J. Short- and Long-Term Renal Outcome of Hemolytic-Uremic Syndrome in Childhood. Front Pediatr 2018;6:220. [PMID: 30131950 DOI: 10.3389/fped.2018.00220] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
23 Joseph A, Cointe A, Mariani Kurkdjian P, Rafat C, Hertig A. Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins (Basel) 2020;12:E67. [PMID: 31973203 DOI: 10.3390/toxins12020067] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
24 Ylinen E, Salmenlinna S, Halkilahti J, Jahnukainen T, Korhonen L, Virkkala T, Rimhanen-Finne R, Nuutinen M, Kataja J, Arikoski P, Linkosalo L, Bai X, Matussek A, Jalanko H, Saxén H. Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome. Pediatr Nephrol 2020;35:1749-59. [PMID: 32323005 DOI: 10.1007/s00467-020-04560-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
25 Lumbreras Fernández J, Cruz Rojo J, Iñigo Martín G, Muley Alonso R, Vara Martín J. [Hemolytic uremic syndrome: long term renal injury]. An Pediatr (Barc) 2010;72:309-16. [PMID: 20347408 DOI: 10.1016/j.anpedi.2009.12.016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
26 Stearns-Kurosawa DJ, Oh SY, Cherla RP, Lee MS, Tesh VL, Papin J, Henderson J, Kurosawa S. Distinct renal pathology and a chemotactic phenotype after enterohemorrhagic Escherichia coli shiga toxins in non-human primate models of hemolytic uremic syndrome. Am J Pathol 2013;182:1227-38. [PMID: 23402998 DOI: 10.1016/j.ajpath.2012.12.026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
27 Oh G, Lau KK. Characteristics of children with sporadic hemolytic uremic syndrome in a single Northern California center. Int Urol Nephrol 2012;44:1467-72. [PMID: 22116676 DOI: 10.1007/s11255-011-0083-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
28 Davis TK, McKee R, Schnadower D, Tarr PI. Treatment of Shiga toxin-producing Escherichia coli infections. Infect Dis Clin North Am 2013;27:577-97. [PMID: 24011831 DOI: 10.1016/j.idc.2013.05.010] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.2] [Reference Citation Analysis]
29 Chami N, Kabyemera R, Masoza T, Ambrose E, Kimaro F, Kayange N, Hokororo A, Furia FF, Peck R. Prevalence and factors associated with renal dysfunction in children admitted to two hospitals in northwestern Tanzania. BMC Nephrol 2019;20:79. [PMID: 30836938 DOI: 10.1186/s12882-019-1254-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Stearns-Kurosawa DJ, Collins V, Freeman S, Debord D, Nishikawa K, Oh SY, Leibowitz CS, Kurosawa S. Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide. Pediatr Nephrol 2011;26:2031-9. [PMID: 21603905 DOI: 10.1007/s00467-011-1913-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
31 Igarashi T, Ito S, Sako M, Saitoh A, Hataya H, Mizuguchi M, Morishima T, Ohnishi K, Kawamura N, Kitayama H. Guidelines for the management and investigation of hemolytic uremic syndrome. Clin Exp Nephrol. 2014;18:525-557. [PMID: 25099085 DOI: 10.1007/s10157-014-0995-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
32 Parello CS, Mayer CL, Lee BC, Motomochi A, Kurosawa S, Stearns-Kurosawa DJ. Shiga toxin 2-induced endoplasmic reticulum stress is minimized by activated protein C but does not correlate with lethal kidney injury. Toxins (Basel) 2015;7:170-86. [PMID: 25609181 DOI: 10.3390/toxins7010170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
33 VanSickle JS, Srivastava T, Alon US. Risk Factors for Short- and Long-Term Outcomes in Children With STEC-HUS/D+ HUS: A Single-Center Experience. Glob Pediatr Health 2018;5:2333794X18816920. [PMID: 30547058 DOI: 10.1177/2333794X18816920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
34 Ardissino G, Tel F, Testa S, Paglialonga F, Longhi S, Martelli L, Consolo S, Picicco D, Dodaro A, Daprai L, Colombo R, Arghittu M, Perrone M, Chidini G, Scalia Catenacci S, Cropanese I, Consonni D; ItalKid-HUS Network. A simple prognostic index for Shigatoxin-related hemolytic uremic syndrome at onset: data from the ItalKid-HUS network. Eur J Pediatr 2018;177:1667-74. [PMID: 30094644 DOI: 10.1007/s00431-018-3198-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]